Nombre del producto:Diethyl 2-oxomalonate

IUPAC Name:1,3-diethyl 2-oxopropanedioate

CAS:609-09-6
Fórmula molecular:C7H10O5
Pureza:95%
Número de catálogo:CM253990
Peso molecular:174.15

Unidad de embalaje Stock disponible Precio($) Cantidad
CM253990-1000g in stock ȌƻDz

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :609-09-6
Fórmula molecular:C7H10O5
Punto de fusión:-
Código de sonrisas:O=C(OCC)C(C(OCC)=O)=O
Densidad:
Número de catálogo:CM253990
Peso molecular:174.15
Punto de ebullición:209°C at 760 mmHg
Nº Mdl:MFCD00009121
Almacenamiento:Keep in inert atmosphere, store at room temperature.

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Sunobinop
Sunobinop is an investigational, novel and potential first-in-class oral compound discovered by Imbrium Therapeutics and that is currently in clinical development. Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP), a protein that is widely expressed in the central and peripheral nervous system and involved in a range of biological functions, including bladder function.
As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.